#China #Beijing #Jacobio Pharma #JAB-23E73 #pan-KRAS Inhibitor

Jacobio Pharma Showcases Pre-Clinical Data of JAB-23E73

Jacobio Pharma, trading under the stock number 1167.HK, recently captured significant attention at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. During the event, held on October 23, 2025, the company presented pre-clinical data for its innovatively developed pan-KRAS inhibitor, JAB-23E73.

The findings from their research underscore the promising potential of JAB-23E73, demonstrating its capabilities as a highly potent pan-KRAS inhibitor that exhibits strong selectivity, notably without affecting HRAS and NRAS inhibition. This remarkable selectivity positions JAB-23E73 as a hopeful candidate in the fight against various cancer types characterized by different KRAS-related mutations or amplifications.

In various in vivo models, specifically KRAS-driven mouse tumor models, JAB-23E73 not only showed considerable efficacy by inducing tumor regression but also did so with an impressive safety profile—resulting in negligible body weight loss, which suggests a wide therapeutic window. Such findings reveal that patients may tolerate this treatment well without harsh adverse effects.

Moreover, the compound displayed commendable pharmacokinetic properties suitable for oral administration. Notably, there was a dose-dependent decrease in phosphorylated ERK (p-ERK) levels observed in the tumors, confirming the medication's action at the molecular level.

Presently, JAB-23E73 is undergoing Phase I clinical trials in both China and the United States. These trials are aimed at evaluating its safety and effectiveness in patients with advanced solid tumors that have KRAS gene alterations, reflecting Jacobio’s commitment to advancing cancer treatment modalities.

About Jacobio Pharma

Jacobio Pharma is steadfast in its mission to deliver breakthrough treatments, focusing heavily on exploring the KRAS pathway with a specialized allosteric drug discovery platform. By integrating sophisticated research and development practices, the company aims to establish itself as a leader in oncology therapeutics. With key research and development centers located in diversified regions such as Beijing and Shanghai in China, and Boston in the USA, Jacobio Pharma is positioning itself to harness innovative strategies that propel cancer research forward.

The company is not only engaged in rigorous clinical trials but also emphasizes entering strategic partnerships that unlock further innovations in cancer therapeutics. With over 180 clinical trial sites throughout China and more than 30 in the U.S., alongside additional locations across Europe, Jacobio Pharma is committed to making substantial strides in the battle against cancer.

For further insights and updates, please visit Jacobio Pharma's official website.